Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats
Feline troglostrongylosis caused by Troglostrongylus brevior is increasingly reported in European countries. Although the disease can be severe and potentially life-threatening, especially in kittens and young cats, effective treatment options are still limited. Two administrations of emodepside 2 w...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Current Research in Parasitology and Vector-Borne Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667114X22000231 |
| _version_ | 1828090648910102528 |
|---|---|
| author | Donato Traversa Simone Morelli Angela Di Cesare Christina Strube Katharina Raue Katrin Bisterfeld Claudia Boehm Matthias Pollmeier Hannah Ringeisen Katrin Blazejak Norbert Mencke |
| author_facet | Donato Traversa Simone Morelli Angela Di Cesare Christina Strube Katharina Raue Katrin Bisterfeld Claudia Boehm Matthias Pollmeier Hannah Ringeisen Katrin Blazejak Norbert Mencke |
| author_sort | Donato Traversa |
| collection | DOAJ |
| description | Feline troglostrongylosis caused by Troglostrongylus brevior is increasingly reported in European countries. Although the disease can be severe and potentially life-threatening, especially in kittens and young cats, effective treatment options are still limited. Two administrations of emodepside 2 weeks apart have shown promising results for the treatment of T. brevior infection in single cases and in a field trial. Therefore, the present study has been conducted to evaluate the efficacy of two spot-on combinations containing emodepside (i.e. 2.14% w/v emodepside and 8.58% w/v praziquantel - Profender®, and 2.04% w/v emodepside, 8.14% w/v praziquantel and 9.79% w/v tigolaner - Felpreva®) in the treatment of troglostrongylosis under experimental conditions. Twenty-four cats were experimentally infected with T. brevior and randomly assigned to one of three groups of eight cats each, i.e. (i) Group 1 (G1) left untreated, (ii) Group 2 (G2) receiving Profender® on Days 28 and 44, and (iii) Group 3 (G3) receiving Felpreva® on Day 28 and Profender® on Day 44. Doses corresponded to the minimum effective dose of 0.140 and 0.148 ml/kg body weight, for Profender® and Felpreva®, respectively. The primary efficacy criterion was the number of viable adult T. brevior counted at necropsy conducted between Days 69 and 72. The fecal shedding of first-stage larvae (L1) was also assessed. L1 of T. brevior were detected in samples from all cats within 20 days post-infection. At necropsy, 4 of 8 G1 cats harbored adult T. brevior, while no adult T. brevior worms or other development stages were recovered from any of the G2 and G3 cats. The primary efficacy criterion was not evaluated as the worm counts in G1 did not meet VICH guideline requirements. After the first treatment (Day 28), most G2 and G3 cats were negative at the Baermann examination. After the second treatment (Day 44), L1 were found in two cats from G2 on Day 49 and in one G3 cat on Day 51. No adverse events occurred in G2 and G3 cats. These results indicate that two applications of emodepside spot-on given 2 weeks apart represent a safe and efficacious treatment regime against troglostrongylosis. |
| first_indexed | 2024-04-11T06:00:06Z |
| format | Article |
| id | doaj.art-aed3df34e60144b1a95150b9d4043f7f |
| institution | Directory Open Access Journal |
| issn | 2667-114X |
| language | English |
| last_indexed | 2024-04-11T06:00:06Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Parasitology and Vector-Borne Diseases |
| spelling | doaj.art-aed3df34e60144b1a95150b9d4043f7f2022-12-22T04:41:43ZengElsevierCurrent Research in Parasitology and Vector-Borne Diseases2667-114X2022-01-012100097Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected catsDonato Traversa0Simone Morelli1Angela Di Cesare2Christina Strube3Katharina Raue4Katrin Bisterfeld5Claudia Boehm6Matthias Pollmeier7Hannah Ringeisen8Katrin Blazejak9Norbert Mencke10Faculty of Veterinary Medicine, University of Teramo, Località Piano DʼAccio, 64100 Teramo (TE), ItalyFaculty of Veterinary Medicine, University of Teramo, Località Piano DʼAccio, 64100 Teramo (TE), ItalyFaculty of Veterinary Medicine, University of Teramo, Località Piano DʼAccio, 64100 Teramo (TE), ItalyInstitute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, Hannover, GermanyInstitute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, Hannover, GermanyInstitute for Parasitology, Centre for Infection Medicine, University of Veterinary Medicine Hannover, Buenteweg 17, Hannover, GermanyBayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, GermanyBayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, GermanyBayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, GermanyVetoquinol S.A., 37 rue de la Victoire, 75009 Paris, FranceVetoquinol S.A., 37 rue de la Victoire, 75009 Paris, France; Corresponding author.Feline troglostrongylosis caused by Troglostrongylus brevior is increasingly reported in European countries. Although the disease can be severe and potentially life-threatening, especially in kittens and young cats, effective treatment options are still limited. Two administrations of emodepside 2 weeks apart have shown promising results for the treatment of T. brevior infection in single cases and in a field trial. Therefore, the present study has been conducted to evaluate the efficacy of two spot-on combinations containing emodepside (i.e. 2.14% w/v emodepside and 8.58% w/v praziquantel - Profender®, and 2.04% w/v emodepside, 8.14% w/v praziquantel and 9.79% w/v tigolaner - Felpreva®) in the treatment of troglostrongylosis under experimental conditions. Twenty-four cats were experimentally infected with T. brevior and randomly assigned to one of three groups of eight cats each, i.e. (i) Group 1 (G1) left untreated, (ii) Group 2 (G2) receiving Profender® on Days 28 and 44, and (iii) Group 3 (G3) receiving Felpreva® on Day 28 and Profender® on Day 44. Doses corresponded to the minimum effective dose of 0.140 and 0.148 ml/kg body weight, for Profender® and Felpreva®, respectively. The primary efficacy criterion was the number of viable adult T. brevior counted at necropsy conducted between Days 69 and 72. The fecal shedding of first-stage larvae (L1) was also assessed. L1 of T. brevior were detected in samples from all cats within 20 days post-infection. At necropsy, 4 of 8 G1 cats harbored adult T. brevior, while no adult T. brevior worms or other development stages were recovered from any of the G2 and G3 cats. The primary efficacy criterion was not evaluated as the worm counts in G1 did not meet VICH guideline requirements. After the first treatment (Day 28), most G2 and G3 cats were negative at the Baermann examination. After the second treatment (Day 44), L1 were found in two cats from G2 on Day 49 and in one G3 cat on Day 51. No adverse events occurred in G2 and G3 cats. These results indicate that two applications of emodepside spot-on given 2 weeks apart represent a safe and efficacious treatment regime against troglostrongylosis.http://www.sciencedirect.com/science/article/pii/S2667114X22000231CatEmodepsideLungwormsTreatmentTroglostrongylus brevior |
| spellingShingle | Donato Traversa Simone Morelli Angela Di Cesare Christina Strube Katharina Raue Katrin Bisterfeld Claudia Boehm Matthias Pollmeier Hannah Ringeisen Katrin Blazejak Norbert Mencke Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats Current Research in Parasitology and Vector-Borne Diseases Cat Emodepside Lungworms Treatment Troglostrongylus brevior |
| title | Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats |
| title_full | Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats |
| title_fullStr | Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats |
| title_full_unstemmed | Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats |
| title_short | Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats |
| title_sort | efficacy of two topical combinations containing emodepside plus praziquantel and emodepside plus praziquantel plus tigolaner for the treatment of troglostrongylosis in experimentally infected cats |
| topic | Cat Emodepside Lungworms Treatment Troglostrongylus brevior |
| url | http://www.sciencedirect.com/science/article/pii/S2667114X22000231 |
| work_keys_str_mv | AT donatotraversa efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT simonemorelli efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT angeladicesare efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT christinastrube efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT katharinaraue efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT katrinbisterfeld efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT claudiaboehm efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT matthiaspollmeier efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT hannahringeisen efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT katrinblazejak efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats AT norbertmencke efficacyoftwotopicalcombinationscontainingemodepsidepluspraziquantelandemodepsidepluspraziquantelplustigolanerforthetreatmentoftroglostrongylosisinexperimentallyinfectedcats |